

Fig. 4 Comparison of SVR rates among groups stratified by drug adherence. The 3 groups of patients divided by the decision tree analysis (white, gray and black boxes indicating a low (L), intermediate (I) and high (H) probability group, respectively) were further stratified according to the cumulative drug exposure of PEG-IFN and RBV. The good adherence group ($\geq 80\%$ planned dose of both PEG-IFN and RBV) had a higher rate of SVR compared with the poor adherence group ($< 80\%$ planned dose of both PEG-IFN and RBV) in the low ($p = 0.0003$) and intermediate ($p = 0.007$) but not in the high probability group ($p = 0.53$)

aimed to develop a pre-treatment model for the prediction of response. To analyze the possible effect of drug reductions on the result of the decision tree analysis, 3 groups of patients divided by the decision tree analysis (low, intermediate and high probability group) were further stratified according to the cumulative drug exposure of PEG-IFN and RBV (Fig. 4). Even after adjustment for adherence, 3 groups of patients still had low, intermediate and high probability of achieving SVR, respectively. Of note, the good adherence group ($\geq 80\%$ planned dose of both PEG-IFN and RBV) had higher rates of SVR compared with the poor adherence group ($< 80\%$ planned dose of both PEG-IFN and RBV) in the low ($p = 0.0003$) and intermediate ($p = 0.007$) probability group, but not in the high probability group ($p = 0.53$).

Factors associated with SVR by multivariate logistic regression analysis

We also explored the factors associated with SVR using a standard statistical analysis. By univariate analysis, age, gender, serum albumin, creatinine, alanine aminotransferase, GGT, red blood cell count, hemoglobin, hematocrit, platelet count and AFP were found to be associated with SVR (Table 2). HCVRNA load was not associated with SVR. By multivariate analysis, age, gender, GGT and platelet count were found to be independently associated with SVR (Table 3). Of note, AFP, which was selected as a

significant predictor of response in the decision tree analysis, was not found to be an independent response predictor in the standard multivariate analysis. This indicates a unique feature of the decision tree analysis; i.e., it could identify significant predictors that specifically apply to selected patients, in this case patients younger than 50 years old.

Relationships between decision tree model and stage of fibrosis or HCV RNA load

Liver biopsy was performed in 664 patients. The distribution of fibrosis in three probability groups differed significantly. Advanced fibrosis (F3 or F4) was higher in the low probability group (39%) compared to the intermediate probability group (13%) ($p < 0.0001$) and to the high probability group (6%) ($p < 0.0001$). Advanced fibrosis was also higher in the intermediate group compared to the high probability group ($p = 0.01$). AFP was significantly associated with liver fibrosis stage: medians of AFP levels were 4.9, 5.9, 13.0 and 18.6 for F1, F2, F3 and F4, respectively ($p < 0.0001$, Spearman's rank correlations). Lower platelet counts correlated with advanced fibrosis stages (data not shown). The SVR rate was higher in the high probability group compared to the intermediate or low probability group after stratification by HCV RNA load. Among patients with low HCVRNA load ($< 400,000$ IU/ml), the rate of SVR was 93, 59 and 50% for the high, intermediate and low probability group, respectively ($p = 0.002$ for high vs. intermediate and $p < 0.001$ for high vs. low probability groups). Among patients with a high HCVRNA load ($\geq 400,000$ IU/ml), the rate of SVR was 73, 42 and 21% for the high, intermediate and low probability group, respectively ($p < 0.001$ for high vs. low, high vs. intermediate and intermediate vs. low probability groups).

Discussion

Currently, the combination of PEG-IFN and RBV is the recommended therapy for chronic HCV infection. The rate of SVR with 48 weeks of therapy is around 50% in patients with HCV genotype 1b and a high HCV RNA titer [2, 3]. To date, the virological response during therapy is the most reliable means for predicting the likelihood of SVR [2, 24, 25]. More potent therapy, such as a triple combination of protease inhibitor, PEG-IFN and RBV, is being evaluated in clinical trials but is not readily available [26, 27]. Under the circumstances, pre-treatment prediction of the likelihood of SVR may be useful for both patients and physicians to support clinical decisions as to whether to start PEG-IFN/RBV therapy or delay treatment until a new more effective therapy becomes available.

Table 2 Comparison of pre-treatment factors between patients with and without sustained virological response (SVR) among the model building dataset ($n = 506$)

	SVR ($n = 240$)	Non-SVR ($n = 266$)	p
Age (years)	54 (25–75)	60 (36–73)	<0.0001
Male gender ^a	151/240 (63%)	171/266 (41%)	<0.0001
Body mass index (kg/m ²)	22.5 (16.8–32.0)	22.6 (15.5–33.3)	0.244
Albumin (g/dl)	4.1 (3.2–5.0)	4 (2.7–4.9)	0.004
Creatinine (mg/dl)	0.7 (0.44–1.14)	0.69 (0.39–1.47)	<0.0001
AST (IU/l)	59 (11–370)	61 (17–261)	0.457
ALT (IU/l)	58 (11–413)	53 (11–316)	0.031
GGT (IU/l)	31 (10–322)	43 (12–328)	0.005
Total cholesterol (mg/dl)	175 (87–297)	171 (73–274)	0.184
Triglyceride (mg/dl)	105 (36–474)	105 (33–294)	0.992
White blood cell count (/μl)	4,600 (2,200–10,900)	4,425 (1,800–10,810)	0.479
Neutrophils (/μl)	2,507 (667–7,870)	2,423 (900–7,281)	0.321
Red blood cell count (/μl)	455 (336–577)	441 (313–564)	0.001
Hemoglobin (g/dl)	14.3 (10.2–17.6)	13.9 (9.4–17.9)	0.004
Hematocrit (%)	42.1 (13.3–53.7)	41.2 (30.7–52.0)	0.031
Platelets (10 ⁹ /l)	178 (81–380)	142 (60–320)	<0.0001
AFP (ng/ml)	4.3 (0.9–680)	6.4 (1.9–468)	0.041
HCVRNA (10 ³ IU/ml)	1,400 (100–5,100)	1,700 (100–5,100)	0.659
Fibrosis stage: F3–4 ^a	21/198 (11%)	52/219 (24%)	<0.0001

Data expressed as median (range) unless otherwise indicated

AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyltransferase, AFP alpha-fetoprotein

^a Data expressed as number/available data (percentage)

Table 3 Multivariate logistic regression analysis for factors associated with sustained virological response (SVR)

	Odds	95% CI	p value
Age (years)	0.96	0.94–0.98	0.001
Platelets (10 ⁹ /l)	1.09	1.04–1.14	<0.0001
ALT (IU/l)	1.01	1.00–1.01	0.001
GGT (IU/l)	0.99	0.98–0.99	<0.0001
Male gender	2.92	1.87–4.55	<0.0001

GGT gamma-glutamyltransferase

Using the data mining analysis, we constructed a simple decision tree model for the pre-treatment prediction of response to PEG-IFN/RBV. The analysis highlighted 5 variables relevant to response: age, gender, platelet count, AFP and GGT. Classification based on these variables identified subgroups of patients with high probabilities of achieving SVR among difficult to treat genotype 1b chronic hepatitis C patients. The reproducibility of the model was confirmed by the independent internal and external validation datasets. An advantage of the decision tree analysis over traditional regression models is that the decision tree model is user-intuitive and can be readily interpreted by medical professionals without any specific knowledge of statistics. Patients can be allocated to specific subgroups with a defined rate of response simply by following the flow-chart form. Using this model, an estimate of the response before treatment can be rapidly obtained, which may facilitate clinical decision making. Thus, this model could be readily applicable to clinical practice.

According to the results of the decision tree analysis, patients were categorized into 3 groups: the rate of SVR was 23–30% for the low probability group, 44–45% for the intermediate probability group and 65–76% for the high probability group. About 30% of patients were each categorized in the high and low probability group and the remaining 40% of patients in the intermediate probability group. These results support the evidence-based approach for selecting an optimum treatment strategy for individual patients. For example, patients in the high probability group may be the most suitable candidates for PEG-IFN/RBV therapy, while patients in the low probability group may be advised to wait for a future therapy, such as the combination of protease inhibitor, PEG-IFN and RBV. However, the estimation of low probability should not be used to preclude patients from therapy, and the final decision should be made on a case-by-case basis, taking into consideration the acceptance by the patient of a low likelihood of response and the potential risk of disease progression while waiting for a future therapy.

Another important finding was that poor adherence to drugs lowered the rate of SVR in the low and intermediate probability groups, which implies that effort should be made to maintain $\geq 80\%$ of the planned dose of PEG-IFN and RBV in those patients. On the other hand, the rate of SVR was high irrespective of drug adherence in the high probability group. Whether shorter duration of therapy is sufficient in this group of patients should be confirmed in future study.

The variables used in the decision tree have been previously reported to associate with the efficacy of IFN therapy. Younger age and male gender are associated with a favorable response [28]. Lower platelet count is a hallmark of advanced fibrosis in chronic hepatitis C and is reported to be associated with poor response to IFN [29]. AFP is usually used for the screening or the diagnosis of hepatocellular carcinoma, but recent studies suggest an association between higher AFP levels and poor response to IFN therapy [30–33]. Previous report speculated that higher expression of AFP by hepatic progenitor cells may be associated with non-response to therapy [30]. Another report speculated that AFP levels predict poor response to therapy through the underlining link to advanced liver fibrosis [31]. Our data support the latter speculation since advanced fibrosis was associated with elevation of AFP levels. Fibrosis of the liver is an important predictor of response, but we did not include this factor in the decision tree analysis since liver biopsy may not always be available in general practice. As a result, two predictive factors that correlate with fibrosis stage (platelet counts and AFP) were selected in the model, and three probability groups reflected the different distribution of fibrosis stage. GGT is reported to be associated with insulin resistance and hepatic steatosis [34–37], a factor that confers resistance to IFN therapy [38–44]. What is unique to the present study is the visualization of response probability by combining these factors and its high reproducibility revealed by a high-quality validation of the model by internal and external validation datasets that were completely independent of the model building dataset. Since factors used in the model were clinical parameters that are readily available by the usual workup of patients, this model could be immediately applicable to clinical practice without imposing costs for additional examinations.

A potential limitation of this study is that data mining analysis has an intrinsic risk of showing relationships that fit to the original dataset but are not reproducible in different populations. Although internal and external validations showed that our model had high reproducibility, we recognize that further validation on a larger external validation cohort, especially in populations other than Japanese, may be necessary to further verify the reliability of our model.

In conclusion, we built a pre-treatment model for the prediction of virological response to PEG-IFN/RBV. Because this decision tree model was made up of simple variables, it can be easily applied to clinical practice. This model may have the potential to support decisions about patient selection for PEG-IFN/RBV based on a possibility of response weighed against the potential risk of adverse events or costs.

Acknowledgments This study was supported by a grant-in-aid from the Ministry of Health, Labor and Welfare, Japan.

References

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology*. 2004;39:1147–71.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002;347:975–82.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. 2001;358:958–65.
4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet*. 2009;41:1105–9.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet*. 2009;41:1100–4.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*. 2009;461:399–401.
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest*. 1995;96:224–30.
8. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med*. 1996;334:77–81.
9. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. *Hepatology*. 1997;25:750–3.
10. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology*. 2005;48:372–80.
11. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. *J Gastroenterol*. 2009;44:952–63.
12. Breiman LJH, Friedman RA, Olshen CJ, Stone CM. *Classification and regression trees*. Calif: Wadsworth; 1980.
13. Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, et al. Improved detection of prostate cancer using classification and regression tree analysis. *J Clin Oncol*. 2005;23:4322–9.
14. Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. *J Epidemiol*. 2002;12:243–8.
15. Averbuch BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center:

- implications on the future of cancer staging. *Surgery*. 2002;132:589–602.
16. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. *J Clin Oncol*. 2004;22:3660–7.
 17. Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol*. 2007;14:34–40.
 18. Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res*. 2005;11:5440–3.
 19. Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, et al. Phosphorus ans an early predictive factor in patients with acute liver failure. *Transplantation*. 2003;75:2007–14.
 20. LeBlanc M, Crowley J. A review of tree-based prognostic models. *Cancer Treat Res*. 1995;75:113–24.
 21. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatol Res*. 2010;40:251–60.
 22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. *Hepatology*. 1996;24:289–93.
 23. Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. *Stat Med*. 1989;8:539–50.
 24. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*. 2003;38:645–52.
 25. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. *Antivir Ther*. 2008;13(Suppl 1):9–16.
 26. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med*. 2009;360:1839–50.
 27. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med*. 2009;360:1827–38.
 28. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. *Dig Dis Sci*. 2009;54:1317–24.
 29. Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? *J Gastroenterol Hepatol*. 2000;15(Suppl):E141–51.
 30. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. *Liver Int*. 2008;28:1112–9.
 31. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol*. 2007;79:1686–95.
 32. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekeciewicz C, et al. Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*. 2007;12:797–803.
 33. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol*. 1998;93:2452–6.
 34. Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyl-transferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. *Hepatology*. 2007;46:158–65.
 35. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, et al. Aminotransferase and gamma-glutamyl-transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. *J Endocrinol Investig*. 2005;28:333–9.
 36. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. *Liver Int*. 2006;26:1119–25.
 37. Yaginuma R, Ikejima K, Okumura K, Kon K, Suzuki S, Takei Y, et al. Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. *Hepatol Res*. 2006;35:19–25.
 38. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology*. 2001;33:1358–64.
 39. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol*. 2007;46:403–10.
 40. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology*. 2003;37:600–9.
 41. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniello R, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. *Dig Dis Sci*. 1994;39:866–70.
 42. Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, et al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol*. 2005;17:149–53.
 43. Vilella-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. *J Clin Gastroenterol*. 2005;39:728–30.
 44. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. *Gut*. 1993;34:1714–7.

Malnutrition Impairs Interferon Signaling Through mTOR and FoxO Pathways in Patients With Chronic Hepatitis C

MASAO HONDA,^{*,‡} KENJI TAKEHANA,[§] AKITO SAKAI,^{*} YUSUKE TAGATA,[§] TAKAYOSHI SHIRASAKI,[‡] SHINOBU NISHITANI,[§] TAKAHIKO MURAMATSU,^{||} TATSUYA YAMASHITA,^{*} YASUNARI NAKAMOTO,^{*} EISHIRO MIZUKOSHI,^{*} YOSHIO SAKAI,^{*} TARO YAMASHITA,^{*} MIKIKO NAKAMURA,^{*} TETSURO SHIMAKAMI,^{||} MINKYUNG YI,[#] STANLEY M. LEMON,^{||} TETSUO SUZUKI,^{**} TAKAJI WAKITA,^{**} SHUICHI KANEKO,^{*} and the Hokuriku Liver Study Group

^{*}Department of Gastroenterology, [‡]Department of Advanced Medical Technology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan; [§]Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals, Co, Ltd, Kanagawa, Japan; ^{||}Frontier Research Labs, Institute for Innovation, Ajinomoto, Co, Inc, Kanagawa, Japan; ^{||}Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; [#]Center for Hepatitis Research, Institute for Human Infections and Immunity, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas; and ^{**}Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan

BACKGROUND & AIMS: Patients with advanced chronic hepatitis C (CH-C) often are malnourished, but the effects of malnutrition on interferon (IFN) signaling and response to treatment have not been determined. We assessed the importance of the nutritional state of the liver on IFN signaling and treatment response. **METHODS:** We studied data from 168 patients with CH-C who were treated with the combination of pegylated-IFN and ribavirin. Plasma concentrations of amino acids were measured by mass spectrometry. Liver gene expression profiles were obtained from 91 patients. Huh-7 cells were used to evaluate the IFN signaling pathway, mammalian target of rapamycin complex 1 (mTORC1), and forkhead box O (FoxO). Antiviral signaling induced by branched-chain amino acids (BCAAs) was determined using the in vitro hepatitis C virus replication system. **RESULTS:** Multivariate logistic regression analysis showed that Fischer's ratio was associated significantly with nonresponders, independent of interleukin-28B polymorphisms or the histologic stage of the liver. Fischer's ratio was correlated inversely with the expression of BCAA transaminase 1, and was affected by hepatic mTORC1 signaling. IFN stimulation was impaired substantially in Huh-7 cells grown in medium that was low in amino acid concentration, through repressed mTORC1 signaling, and increased Socs3 expression, which was regulated by Foxo3a. BCAA could restore impaired IFN signaling and inhibit hepatitis C virus replication under conditions of malnutrition. **CONCLUSIONS: Malnutrition impaired IFN signaling by inhibiting mTORC1 and activating Socs3 signaling through Foxo3a. Increasing BCAAs to up-regulate IFN signaling might be used as a new therapeutic approach for patients with advanced CH-C.**

Keywords: HCV; Liver Disease; Therapy; Diet.

Interferon (IFN) and ribavirin (RBV) combination therapy is a popular modality for treating patients with chronic hepatitis C (CH-C), but approximately 50% of patients usually relapse, particularly those with hepatitis C virus (HCV) genotype 1b and a high viral load.¹

Recent landmark studies of genome-wide associations identified genomic loci associated with treatment responses to pegylated (Peg)-IFN and RBV combination therapy,^{2,3} and a polymorphism in the interleukin (IL)-28B gene was found to predict hepatitis C treatment-induced viral clearance. Moreover, we previously showed that expression of hepatic IFN-stimulated genes (ISGs) was associated with the IL-28B polymorphism and might contribute to the treatment response.⁴ In addition to the IL-28B polymorphism, host factors such as fibrosis stage and metabolic status of the liver might be associated with the treatment outcome^{4,5}; however, the significance of these factors in conjunction with the IL-28B polymorphism has not been evaluated fully.

In CH-C livers, prolonged liver cell damage, fibrosis development, and microcirculation failure can lead to a state of malnutrition in hepatocytes, resulting in the impairment of multiple metabolic pathways. In patients with advanced stage CH-C, hypoalbuminemia and decreased plasma values for the Fischer's ratio of branched-amino acids (BCAA; leucine, isoleucine, and valine) to aromatic amino acids (tyrosine and phenylalanine) commonly are observed. BCAA are the essential amino acids necessary for ammonium metabolism in muscle when the liver is unable to perform this function. Recent reports have shown that BCAA activates albumin synthesis in rat

Abbreviations used in this paper: BCAA, branched-chain amino acid; BCAT1, branched chain amino-acid transaminase 1; CH-C, chronic hepatitis C; ChIP, chromatin immunoprecipitation; DMEM, Dulbecco's modified Eagle medium; FBE, Foxo binding element; FBEmut, Foxo binding element mutant; FoxO, forkhead box, subgroup O; GLuc, Gaussia luciferase; IFN, interferon; IL, interleukin; ISG, interferon-stimulated genes; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; NR, no response; PCR, polymerase chain reaction; Peg, pegylated; p-mTOR, phosphorylated form of mammalian target of rapamycin; pS6K, phosphorylated form of p70 S6 protein kinase; pSTAT1, phosphorylated form of signal transducer and activator of transcription 1; Raptor, regulatory associated protein of mTOR; RBV, ribavirin; S6K, p70 S6 protein kinase; siRNA, small interfering RNA; SVR, sustained viral response; TR, transient response.

© 2011 by the AGA Institute

0016-5085/\$36.00

doi:10.1053/j.gastro.2011.03.051

primary hepatocytes⁶ and cirrhotic rat liver⁷ through mammalian target of rapamycin (mTOR) signaling, a central regulator of protein synthesis, by sensing nutrient conditions.⁸ Thus, peripheral amino acid composition is closely related to signaling pathways in the liver.

In addition to metabolic aspects, recent reports have elucidated new functional roles for mTOR in the IFN signaling pathway. Targeted disruptions of tuberous sclerosis 2 and eukaryotic translation initiation factor 4E binding protein 1, which both inhibit mTOR complex 1 (mTORC1) signaling, substantially enhanced IFN- α -dependent antiviral responses.^{9,10} Therefore, mTORC1 signaling might be involved in the antiviral response as well as in metabolic processes. However, these issues have not yet been addressed in terms of IFN treatment for CH-C. In the present study, therefore, we evaluated the clinical relevance of the nutritional state of the liver, as estimated by the plasma Fischer's ratio, on Peg-IFN and RBV combination therapy. We also evaluated antiviral signaling induced by BCAA using an *in vitro* HCV replication system.

Materials and Methods

Patients

A total of 168 patients with CH-C at the Graduate School of Medicine at Kanazawa University Hospital (Kanazawa, Japan) and its related hospitals in Japan (Table 1, Supplementary Table 1) were evaluated in the present study. The clinical characteristics of these patients have been described previously.⁴ All patients were administered Peg-IFN- α 2b (Schering-Plough K.K., Tokyo, Japan) and RBV combination therapy for 48 weeks. The definition of the treatment response was as follows: sustained viral response (SVR), clearance of HCV viremia 24 weeks after the cessation of therapy; transient response (TR), no detectable HCV viremia at the cessation of therapy but relapse during the follow-up period; and no response (NR). Genetic variation of the IL-28B polymorphism at rs8099917 was evaluated in all patients using TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA) as described previously.⁴ Gene expression profiling in the liver was performed in 91 patients using the Affymetrix Human 133 Plus 2.0 microarray chip (Affymetrix, Santa Clara, CA) as described previously (Supplementary Table 1).⁴

Plasma Amino Acid Analysis

Amino acid concentrations in plasma samples were measured by high-performance liquid chromatography-electrospray ionization-mass spectrometry, followed by derivatization.¹¹ Detailed experimental procedures are described in the Supplementary Materials and Methods section.

Culture Medium

Huh-7 and Huh-7.5 cells (kindly provided by Professor C. M. Rice, Rockefeller University, New York, NY) were maintained in Dulbecco's modified Eagle medium (DMEM; Gibco BRL, Gaithersburg, MD) containing 10%

fetal bovine serum and 1% penicillin/streptomycin (normal medium). Amino acid-free medium (ZERO medium) was prepared by mixing 5.81 g nutrition-free DMEM (Nacalai Tesque, Kyoto, Japan), 1.85 g NaHCO₃, 1 g glucose, and 0.5 mL 1M (mol/L) sodium pyruvate in 500 mL Milli-Q water, then sterilizing with a 0.22- μ m filter (Millipore, Billerica, MA). Low amino acid media ($\times 1/5$, $\times 1/10$, $\times 1/30$, and $\times 1/100$ DMEM) were prepared by diluting $\times 1$ DMEM with ZERO medium. Powdered BCAA (leucine-isoleucine-valine, 2:1:1.2) (Ajinomoto Pharma, Tokyo, Japan) was freshly dissolved with distilled water at 100 mmol/L, then applied to cultured medium at 2 mmol/L, 4 mmol/L, or 8 mmol/L.

Western Blotting and Immunofluorescence Staining

A total of 1.5×10^5 Huh-7 cells were seeded in normal medium 24 hours before performing the experiments. The medium was changed to low-amino-acid medium and maintained for up to 24 hours. Western blotting was performed as previously described.¹² Cells were washed in phosphate-buffered saline (PBS) and lysed in RIPA buffer containing complete Protease Inhibitor Cocktail and PhosSTOP (Roche Applied Science, Indianapolis, IN). The membranes were blocked in Blocking One-P (Nacalai Tesque). The antibodies used for Western blotting are summarized in the Supplementary Materials and Methods section.

For immunofluorescence staining, cells were fixed with 4% paraformaldehyde in PBS, then permeabilized with 0.1% Triton-X 100 in PBS. The primary anti-forkhead box O (Foxo)3a antibody (Abcam, Cambridge, MA) was used at a final concentration of 2 μ g/mL in PBS containing 2% fetal bovine serum at 4°C for 16 hours. Incubation with the Alexa Fluor 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA) at a 500-fold dilution in PBS containing 3% fetal bovine serum antibody was performed for 4 hours, and cells were stained with Hoechst 33258 to visualize nuclear DNA (Vector Laboratories, Burlingame, CA).

Quantitative Real-Time Detection Polymerase Chain Reaction

A total of 1.5×10^5 Huh-7 cells were seeded in normal medium 24 hours before performing the experiments. The medium was changed to low-amino-acid medium, to which IFN- α and/or BCAA was added, and maintained for 24 hours. Rapamycin treatment (100 nmol/L) was performed for 30 minutes in normal medium before a medium change. RNA was isolated using TriPure isolation reagent (Roche Applied Science), and complementary DNA (cDNA) was synthesized using the High Capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). Real-time detection polymerase chain reaction (PCR) was performed using the 7500 Real-Time PCR System (Applied Biosystems) and Power SYBR Green PCR Master Mix (Applied Biosystems) containing specific primers according to the manufacturer's

Table 1. Comparison of Clinical Factors Between Patients With and Without NR

Clinical category	SVR+TR	NR	Univariate P value	Multivariate odds (95% CI)	Multivariate P value
Patients, n	125	43		—	
Age and sex					
Age, y	57 (30–72)	56 (30–73)	.927	—	
Sex, male vs female	68 vs 57	24 vs 19	.872	—	
Liver histology					
F stage (F1–2 vs F3–4)	95 vs 30	20 vs 23	.001	6.35 (2.02–23.7)	.001
A grade (A0–1 vs A2–3)	68 vs 57	19 vs 24	.248	—	
Host gene factors					
IL-28B (TT vs TG/GG) ^a	109 vs 12	12 vs 31	<.001	19.7 (5.74–82.7)	<.001
ISGs (Mx, IFI44, IFIT1), (<3.5 vs ≥3.5)	103 vs 22	12 vs 31	<.001	5.26 (1.65–17.6)	.005
Metabolic factors					
BMI, kg/m ²	23.2 (16.3–34.7)	23.4 (19.5–40.6)	.439	—	
TG, mg/dL	98 (30–323)	116 (45–276)	.058	—	
T-Chol, mg/dL	167 (90–237)	160 (81–214)	.680	—	
LDL-Chol, mg/dL	82 (36–134)	73 (29–123)	.019	—	
HDL-Chol, mg/dL	42 (20–71)	47 (18–82)	.098	—	
FBS, mg/dL	94 (60–291)	96 (67–196)	.139	—	
Insulin, μU/mL	6.6 (0.7–23.7)	6.8 (2–23.7)	.039	—	
HOMA-IR	1.2 (0.3–11.7)	1.2 (0.4–7.2)	.697	—	
Fischer ratio	2.3 (1.5–3.3)	2.1 (1.5–2.8)	.005	8.91 (1.62–55.6)	.011
Other laboratory parameters					
AST level, IU/L	46 (18–258)	64 (21–283)	.017	—	
ALT level, IU/L	60 (16–376)	82 (18–345)	.052	—	
γ-GTP level, IU/L	36 (4–367)	75 (26–392)	<.001	—	
WBC, /mm ³	4800 (2100–11100)	4800 (2500–8200)	.551	—	
Hb level, g/dL	14 (9.3–16.6)	14.4 (11.2–17.2)	.099	—	
PLT, ×10 ⁴ /mm ³	15.7 (7–39.4)	15.2 (7.6–27.8)	.378	—	
Viral factors					
ISDR mutations ≤1 vs ≥2	80 vs 44	34 vs 9	.070	4.12 (1.25–15.9)	.019
HCV-RNA, KIU/mL	2300 (126–5000)	1930 (140–5000)	.725	—	
Treatment factors					
Total dose administered					
Peg-IFN, μg	3840 (960–7200)	3840 (1920–2880)	.916	—	
RBV, g	202 (134–336)	202 (36–336)	.531	—	
Achieved administration rate					
Peg-IFN, %					
≥80%	84	28	.975	—	
<80%	42	14			
RBV (%)					
≥80%	76	24	.745	—	
<80%	50	18			
Achievement of EVR	101/125 (81%)	0/43 (0%)	<.001	—	

BMI, body mass index; CI, confidence interval; FBS, fasting blood sugar; γ-GTP, gamma-glutamyl transpeptidase; Hb, hemoglobin; HDL-cholesterol, high density lipoprotein cholesterol; LDL-cholesterol, low density lipoprotein cholesterol; PLT, platelets; T-cholesterol, total cholesterol; TG, triglycerides; WBC, leukocytes.

^aIL-28B SNP at rs8099917.

instructions. The primer sequence for real-time detection PCR is given in the Supplementary Materials and Methods section. HCV RNA was detected as described previously¹² and expression was standardized to that of glyceraldehyde-3-phosphate dehydrogenase.

Reporter Assay

Construction of the interferon stimulated response element (ISRE)-luc reporter plasmid and Socs3-luc or Socs3 (FoxO binding element mutant [FBEmut])-luc reporter plasmids is described in the Supplementary Materials and Methods section.

Huh-7 cells were transfected with the ISRE-luc reporter plasmid 24 hours before IFN-alfa treatment. Cells were

treated with IFN-alfa (0 or 100 U/mL) and BCAA (2 mmol/L) in low-amino-acid media. After 24 hours, luciferase activities were measured using the Dual Luciferase assay system (Promega, Madison, WI). For Socs3 promoter activities, Huh-7 cells were transfected with Socs3-luc or Socs3 (FBEmut)-luc reporter plasmids together with the Foxo3a expression plasmid, and luciferase activities were measured after 24 hours. Values were normalized to the luciferase activity of the co-transfected pGL4.75 Renilla luciferase-expressing plasmid (Promega).

Knockdown Experiments

Huh-7 cells were transfected with Ctrl (Stealth RNAi Negative Control Low GC Duplex #2; Invitrogen) or

targets (regulatory associated protein of mTOR [Raptor] and Foxo3a) (Supplementary Materials and Methods) small interfering RNA (siRNA) using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's instructions. After 48 hours, cells were cultured in normal or low-amino-acid media for a further 24 hours. The knockdown effect was confirmed by Western blotting.

Chromatin Immunoprecipitation Assay

Detailed experimental procedures are described in the Supplementary Materials and Methods section.

HCV Replication Analysis

pH77S3 is an improved version of pH77S, a plasmid containing the full-length sequence of the genotype 1a H77 strain of HCV with 5 cell culture-adaptive mutations that promote its replication in Huh-7 hepatoma cells.¹³ pH77S.3/Gaussia luciferase (GLuc)2A is a related construct in which the GLuc sequence, fused to the 2A autocatalytic protease of foot-and-mouth virus RNA, was inserted in-frame between p7 and NS2¹⁴ (Supplementary Materials and Methods). A signal sequence in GLuc directs its secretion into cell culture media, allowing real-time, dynamic measurements of GLuc expression to be performed without the need for cell lysis.

A 10- μ g aliquot of synthetic RNA transcribed from pH77S.3/GLuc2A was used for electroporation. Cells were pulsed at 260 V and 950 μ F using the Gene Pulser II apparatus (Bio-Rad Laboratories, Hercules, CA) and plated in fresh normal medium for 12 hours to recover. Cell medium was changed to \times 1 DMEM without serum for 8 hours, then changed to low-amino-acid medium containing 0–8 mmol/L BCAA for a further 24 hours. Cells and culture medium were collected and used for GLuc assays, real-time detection PCR, and Western blotting. The number of viable cells was determined by a (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay (Promega).

Continuously JFH-1-infecting Huh-7 cells were obtained by the infection of Huh-7 cells with JFH-1 cell culture-derived HCV at a multiplicity of infection of 0.01. Cells were maintained in normal medium by passaging every 3–4 days for approximately 6 months. About 20%–30% of the cells consistently were positive for HCV core protein (Supplementary Figure 4). Culture medium of JFH-1-infecting Huh-7 cells was changed to the low-amino-acid medium containing 0–8 mmol/L BCAA for 24 hours. Cells then were collected and used for assays.

Statistical Analysis

Results are expressed as mean \pm standard deviation. Significance was tested by 1-way analysis of variance with the Bonferroni method, and differences were considered statistically significant at a *P* value of less than .05.

Results

Fischer's Ratio as a Predictive Factor for Treatment Response

The clinical characteristics of patients who received Peg-IFN and RBV combination therapy are shown in Table 1 and Supplementary Table 1, and explanations of these characteristics have been described previously.⁴ All patients were infected with HCV genotype 1b and had a high viral load (>100 IU/mL). We compared patients with SVR + TR against those with NR, as assessed by the overall plausibility of treatment response groups using Fisher's C statistic as previously described.⁴ We included data on the IL-28B polymorphism and plasma amino acid composition (aminogram).

Univariate regression analysis showed that no single amino acid was associated significantly with treatment response; however, using Fischer's ratio, the BCAA (Ile+Leu+Val)/aromatic amino acids (Phe+Tyr) ratio was associated significantly with treatment response (*P* = .005) (Table 1). Of the 121 patients with IL-28B major type, SVR, TR, and NR were observed in 53%, 37%, and 10%, respectively, and among 33 patients with IL-28B minor type, SVR, TR, and NR were observed in 15%, 17%, and 68%, respectively (*P* < .001) (data not shown). Fischer's ratio of SVR, TR, and NR was 2.35 ± 0.38 , 2.30 ± 0.29 , and 2.10 ± 0.31 , respectively (*P* < .015) (data not shown).

We selected IL-28B polymorphism, hepatic ISG expression, fibrosis stage, HCV RNA, interferon sensitivity determining region mutation, and Fischer's ratio as factors for multivariate analysis. Multivariate analysis revealed that the minor type of IL-28B polymorphism (TG or GG at rs8099917) (odds ratio, 19.7; *P* < .001), advanced fibrosis stage of the liver (F3–4) (odds ratio, 6.35; *P* = .001), high hepatic ISGs (≥ 3.5) (odds ratio, 5.26; *P* = .005), low Fischer's ratio (continuous range, 1.5–3.3) (unit odds, 8.91; *P* = .011), and presence of ISDR mutation (≤ 1) (odds ratio, 4.12; *P* = .019) independently contributed to NR (Table 1).

The distribution of the Fischer's ratio according to fibrosis stage is shown in Supplementary Figure 1. The ratio decreased significantly in advanced fibrosis stage (F3–4) compared with early fibrosis stage (F1). No significant association between major or minor type of IL-28B polymorphism and different fibrosis stages of the liver was observed (Supplementary Figure 1A). In early fibrosis (F1–2) (Supplementary Figure 1B), 90% (80 of 89) of SVR+TR cases had the major type of IL-28B polymorphism, and 94% (16 of 17) of NR cases had the minor type. However, in the advanced fibrosis stage of the liver (F3–4) (Supplementary Figure 1C), 85% (23 of 27) of SVR+TR cases had the major type of IL-28B polymorphism and 50% (10 of 20) of NR cases had the minor type. Thus, in advanced fibrosis stages, factors other than the IL-28B polymorphism appear to contribute to NR. Interestingly, the Fischer's ratio was significantly lower in NR patients than SVR+TR pa-

tients in the advanced fibrosis stage of the liver. Therefore, Fischer's ratio could be an important predictor for NR that is independent of IL-28B polymorphism and histologic stage of the liver.

Fischer's Ratio and mTORC1 Signaling in CH-C Livers

Hepatic gene expression in 91 of 168 patients (Supplementary Table 1) was obtained using Affymetrix genechip analysis as described previously.⁴ To examine the relationship between the plasma Fischer's ratio and mTORC1 signaling in the liver we evaluated the expression of key regulatory genes related to mTORC1 signaling. We found that expression of branched chain amino acid transaminase 1 (BCAT1), an important catalytic enzyme of BCAA, was significantly negatively correlated with Fischer's ratio (Figure 1A). This indicates that the plasma Fischer's ratio is regulated in the liver as well as in peripheral muscle. Interestingly, the expression of *c-myc*, a positive regulator of BCAT1 (Figure 1C),¹⁵ was correlated negatively with the Fischer's ratio (Figure 1B). The expression of PDCD4, a negative transcriptional target of ribosomal p70 S6 protein kinase (S6K), downstream of mTORC1, was correlated significantly with BCAT1 (Figure 1D and E). Thus, in CH-C livers, BCAT1 is induced with progressive liver disease and mTORC1 signaling is repressed, a process that might involve *c-myc*. Fischer's ratio of the plasma therefore can be seen to reflect mTORC1 signaling in the liver.

Impaired IFN Signaling in Huh-7 Cells Grown in Low-Amino-Acid Medium

Recent reports have shown the functional relevance of mTOR on IFN signaling and antiviral responses.^{9,10} To evaluate IFN- α signaling and the mTOR pathway, we used Huh-7 cells grown in different amino acid conditions ($\times 1$ DMEM; $\times 1/5$ DMEM, $\times 1/30$ DMEM, and $\times 1/100$ DMEM). The phosphorylated forms of mTOR (p-mTOR) and S6K (pS6K), an important downstream regulator of mTORC1 signaling, were decreased substantially in $\times 1/30$ DMEM and $\times 1/100$ DMEM (Figure 2A). Interestingly, the expression of the phosphorylated form of signal transducer and activator of transcription 1 (pSTAT1), an essential transducer of type 1 IFN signaling, also was decreased in these conditions (Figure 2A). Similarly, the expression of p-mTOR and pSTAT1 was repressed significantly in CH-C livers with a low Fischer's ratio compared with those with a high Fischer's ratio (Supplementary Figure 2, Supplementary Table 2).

To examine whether decreased pSTAT1 expression might be owing to repressed mTORC1 signaling, we knocked down the expression of Raptor, a specific subunit of mTORC1. We achieved more than 50% knockdown of Raptor by specific siRNA (Figure 2B). Under these conditions, the expression of p-mTOR and pS6K were repressed, which is consistent with previous reports.¹⁶ The expression of pSTAT1 also was repressed after Raptor knockdown (Figure 2B).




Figure 1. Regression analysis of mTORC1-related gene expression in liver. Gene expression values were determined by probe intensities. (A) BCAT1 and Fischer's ratio. (B) *c-myc* and Fischer's ratio. (C) BCAT1 and *c-myc*. (D) PDCD4 and BCAT1. (E) Putative signaling of mTORC1-related genes in CH-C.




Figure 2. mTORC1 and IFN signaling in Huh-7 cells in low-amino-acid medium. (A) p-mTOR, pS6K, and pSTAT1 expression in different amino acid media. (B) p-mTOR, pS6K, and pSTAT1 expression under Raptor knock-down conditions. (C) IFN- α stimulation and pSTAT1 expression in low-amino-acid media or under Raptor knock-down conditions. (D) IFN- α stimulation and ISRE reporter activities in normal and low-amino-acid media. (E) IFN- α stimulation and 2'5'OAS expression supplemented with BCAA or rapamycin in low-amino-acid medium. (F) Chromatin immunoprecipitation of 2'5'OAS promoter region by ISGF3 γ .

The induction of pSTAT1 by IFN- α (1000 U/mL) stimulation was impaired in $\times 1/5$ DMEM or in Raptor knocked-down condition, compared with the control (Figure 2C). Consistent with these results, IFN- α -induced ISRE-dependent transcriptional activity, as measured using an ISRE-luciferase reporter assay, was impaired significantly in $\times 1/5$ DMEM compared with $\times 1$ DMEM (Figure 2D). However, this activity could be rescued by the addition of 2 mmol/L BCAA (Figure 2D). These results were confirmed by determining the expression of the endogenous IFN- α responsive gene, 2'5'OAS, using quantitative reverse-transcription PCR. Figure 2E shows that BCAA treatment augmented 2'5'OAS expression in low levels of amino acids, and that this could be reversed by the addition of rapamycin, an inhibitor of mTORC1 (Figure 2E). Furthermore, chromatin immunoprecipitation (ChIP) experiments revealed that transcriptional augmentation by BCAA was mediated by the binding of the IFN- α -inducible transcription factor, ISGF3 γ , to the promoter region of 2'5'OAS (Figure 2F). These results indicate that

amino acids in culture media play an essential role in IFN- α signaling through mTORC1 signaling, and that the addition of BCAA can overcome impaired IFN- α signaling in Huh-7 cells.

Induction of Socs3 in Low-Amino-Acid Medium in Huh-7 Cells

Besides being involved in mTOR signaling, Foxo transcriptional factors mediate another important branch of nutrition-sensing signaling pathway.¹⁷ Therefore, we evaluated forkhead box O3A (Foxo3a) expression in low-amino-acid conditions in Huh-7 cells. After 6 hours culture in $\times 1/5$, $\times 1/30$, and $\times 1/100$ DMEM, expression of the phosphorylated form of Foxo3a (pFoxo3a) decreased, whereas that of total Foxo3a increased in $\times 1/5$ and $\times 1/30$ DMEM, and the ratio of pFoxo3a to Foxo3a (pFoxo3a/Foxo3a) substantially decreased (Figure 3A and B). It has been reported that dephosphorylated Foxo3a is translocated to the nucleus before activation of its target genes.¹⁸ In the present study, immunofluorescent staining




Figure 3. Foxo3a and Socs3 signaling in Huh-7 cells in low-amino-acid medium. (A) Foxo3a and Socs3 expression in different amino acid media. (B) Relative change of pFoxo3a/Foxo3a and Socs3 expression in different amino acid media. (C) Immunofluorescence staining of Foxo3a in Huh-7 cells in normal and low-amino-acid media. (D) Relative change of Socs3 messenger RNA in Huh-7 cells in normal and low-amino-acid media. (E) Regression analysis of Socs3 in liver and Fischer's ratio. (F) Regression analysis of Socs3 and Foxo3a in liver.

with an anti-Foxo3a antibody showed that Foxo3a diffused in both the cytoplasm and nucleus in normal amino acid medium, but localized in the nucleus in low-amino-acid medium ($\times 1/10$ DMEM) (Figure 3C).

Interestingly, in low-amino-acid medium, transcription and protein expression of Socs3 increased significantly (Figure 3A, B, and D). The induction of Socs3 in a state of malnutrition also was confirmed in clinical samples. In CH-C livers there was a significant negative correlation

between the plasma Fischer's ratio and Socs3 expression, implying that Socs3 expression increases during the malnutrition state induced by CH-C. There was also a significant correlation between Foxo3a and the transcriptional level of Socs3 in CH-C livers (Figure 3E and F), suggesting an *in vitro* and *in vivo* biological role for Foxo3a in the activation of Socs3 expression. These findings also were confirmed by Western blotting of CH-C livers (Supplementary Figure 2, Supplementary Table 2).

Socs3 Is a Transcriptional Target of Foxo3a

The significant correlation between *Socs3* and *Foxo3a* in CH-C livers prompted us to analyze the *Socs3* promoter sequence and, in doing so, we identified a putative *Foxo* binding element (FBE) (Figure 4A). To investigate the functional relevance of *Foxo3a* in the transcriptional regulation of *Socs3*, we constructed reporter plasmids containing a luciferase coding region fused to the *Socs3* promoter region (*Socs3-luc*). *Socs3-luc* promoter activity was increased substantially by the overexpression of *Foxo3a* (Figure 4B). The mutations introduced in the putative FBE (FBE_{mut}) in the *Socs3* promoter significantly reduced *Foxo3a*-induced *Socs3* promoter activation (Figure 4B).

Foxo3a then was knocked down by siRNA and *Socs3* induction was evaluated. After suppression of *Foxo3a* (Supplementary Figure 3), *Socs3* promoter activity was repressed significantly in low-amino-acid medium ($\times 1/10$ DMEM) (Figure 4C). Thus, *Foxo3a* appears to be indispensable for activating the *Socs3* promoter under low-amino-acid conditions. Correlating with these results, ChIP assays using an anti-*Foxo3a* antibody showed a significant increase in the association between *Foxo3a* and the FBE of the *Socs3* promoter in low-amino-acid conditions ($\times 1/10$ DMEM) (Figure 4D). Taken together, these results suggest that, besides mTORC1 signaling, the *Foxo3a*-mediated *Socs3* signaling pathway might contribute to impaired IFN signaling in a state of malnutrition in CH-C. BCAA potentially restores this signaling (Figure 4E).

Effect of BCAA on HCV Replication in Huh-7 or Huh-7.5 Cells

Based on the earlier-described results, we used 2 HCV in vitro replication systems to examine whether BCAA affects HCV replication in Huh-7 or Huh-7.5 cells. The first system used a recombinant infectious genotype 1a clone, H77S.3/GLuc2A (Supplementary Materials and Methods, Supplementary Figure 4), including reporter genes, whereas the second used continuously JFH-1-infecting Huh-7 cells (Supplementary Materials and Methods).

The synthetic RNA transcribed from pH77S.3/GLuc2A was introduced into Huh-7.5 cells and replication of H77S.3/GLuc2A was evaluated in normal or low-amino-acid medium supplemented with BCAA. H77S.3/GLuc2A increased significantly by 2.6-fold in Huh-7.5 cells grown in low-amino-acid medium ($\times 1/5$ DMEM) compared with normal amino acid medium ($\times 1$ DMEM). Interestingly, BCAA repressed H77S.3/GLuc2A replication in a dose-dependent manner (Figure 5A). In agreement with these results, the expression of Mx-1 was increased significantly by the addition of BCAA (Figure 5B). Similar findings were observed in JFH-1-infecting Huh-7 cells (Materials and Methods, Supplementary Figure 4). Although no obvious increase in HCV replication was observed in low-amino-acid medium ($\times 1/5$ DMEM) com-

pared with normal amino acid medium ($\times 1$ DMEM), JFH-1 replication was repressed significantly by the addition of BCAA in a dose-dependent manner (Figure 5D). The expression of Mx-1 was increased substantially by the addition of BCAA (Figure 5E), suggesting that BCAA significantly repressed HCV replication in cells with either naive or persistent HCV infection. Importantly, there were no significant differences in cell viability between the conditions (Figure 5C and F).

To validate these findings, signaling pathways in HCV replicating cells were examined (Figure 6A and B). BCAA increased pS6K in a dose-dependent manner, implying its involvement in the activation of mTORC1 signaling. Related to this, expression of pSTAT1 was shown to be increased and the ratio of pSTAT1 to total STAT1 (pSTAT1/STAT1) increased 2.5- to 3-fold after the addition of BCAA. Thus, BCAA activated mTORC1 and the JAK-STAT signaling pathway in HCV-infected cells. In addition, the expression ratio of pFoxo3a to total Foxo3a (pFoxo3a/Foxo3a) increased 3- to 4-fold, indicating an increase in the cytoplasmic form of Foxo3a that is exposed to proteasome degradation. Concordant with these findings, we observed a decrease in the expression of *Socs3*. In addition, expression of the HCV core protein decreased as shown in Figure 6A and B. Thus, these results clearly show that BCAA repressed HCV replication through activation of IFN signaling and repression of *Socs3*-mediated IFN inhibitory signaling, as proposed in Figure 4E.

Discussion

Thompson et al⁵ showed that the IL-28B polymorphism, HCV RNA, nationality (Caucasian/Hispanic vs African American), hepatic fibrosis stage, and fasting blood sugar level are all significant variables for achieving SVR in patients infected with genotype 1 HCV. However, the significance of variable factors for treatment response in conjunction with the IL-28B polymorphism has not been evaluated fully. In the present study, in addition to previously examined variables,⁴ we included the plasma Fischer's ratio as a nutritional parameter. Multivariate analysis showed that the minor type of IL-28B polymorphism, advanced fibrosis stage, high hepatic ISGs, low Fischer's ratio, and ISDR mutation (≤ 1) independently contributed to NR (Table 1). Interestingly, among patients of similar fibrosis stage (F3-4), the Fischer's ratio was significantly lower in NR than SVR+TR cases. Therefore, the plasma value of Fischer's ratio was associated with the treatment response that was independent of the IL-28B polymorphism and histologic stage of the liver, although patients with advanced hepatic fibrosis are likely to be nutritionally affected.

As a nutrient sensor signaling pathway, the protein kinase mTOR plays an essential role in maintaining homeostasis and regulates protein synthesis in response to nutrient conditions. mTOR is the catalytic subunit of 2 distinct complexes, mTORC1 and mTORC2. In addition

A

Socs3 promoter

```

Human  --CGCCCTCG GCGCCCGCGG CCCCTCCCTC ACCCTCCGCG CTCAGCCTTT CTCTGCTGCG
      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mouse  TCCAAGCCCG CCTCCTCGCG CCCCTCCCTC GCCCTCCGCG CACAGCCTTT CAGTGC--AG

      FBE                               GAS
AGTAGTGACT AAACATTACA AGAAGGCCGG CCGCGCAGTT CCAGGAATCG GGGGGCGGGG
      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AGTAGTGACT AAACATTACA AGAAGACCGG CCGGGCAGTT CCAGGAATCG GGGGGCGGGG

      TATA                               Transcription start site
CGCGGCGGCC GCCTATATAC CCGCGAGCGC GGCCTCCGCG GCGGCTC
      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CGTACTGGCC GGTAAATAC CCGCGCGCGC GGCCTCCGAG GCGGCTC
    
```


FBE of Socs3 promoter

Wild seq. TGACTAAACATTACA


Mutated seq. TGACTCACCATTACA

Consensus seq. (G/A)TAAA(T/C)A


B



C



D



E




Figure 4. Socs3 promoter assay. (A) Primary structure of putative Foxo binding element in Socs3 promoter region. (B) Socs3-luc and Socs3 (FBEmut)-luc activities after overexpression of Foxo3a in Huh-7 cells. (C) Relative Socs3 messenger RNA (mRNA) expression after knockdown of Foxo3a in normal and low-amino-acid media. (D) Chromatin immunoprecipitation of Socs3 promoter region by Foxo3a in normal and low-amino-acid media. (E) Model of impaired IFN signaling by repressed mTORC1 signaling and increased Socs3 signaling under CH-C state of malnutrition.




Figure 5. Effect of BCAA on HCV replication in cells in low-amino-acid medium. (A) Effect of BCAA on H77S.3/GLuc2A replication in Huh-7.5 cells. (B) Mx-1 expression in H77S.3/GLuc2A-transfected Huh-7.5 cells supplemented with BCAA. (C) Viability of Huh-7.5 cells. (D) Effect of BCAA on JFH-1 replication continuously infecting Huh-7 cells. (E) Mx-1 expression in continuously JFH-1-infecting Huh-7 cells supplemented with BCAA. (F) Viability of Huh-7 cells.

to these metabolic aspects, recent reports have shown that mTORC1 participates in IFN signaling and antiviral defense responses,^{9,10} although the precise signaling pathway has not yet been clarified. In the present study, we evaluated mTORC1 signaling in CH-C livers using gene expression profiling of 91 patients (Figure 1, Supplementary Table 1). We observed a significant negative correlation between plasma Fischer's ratio and hepatic expression of BCAT1, an important catalytic enzyme of BCAA (Figure 1A). Moreover, BCAT1 expression was correlated positively with PDCD4 expression, which in turn is regulated negatively by pS6K at the transcriptional level (Figure 1D).¹⁶ Thus, the expression of BCAT1 appears to be a negative indicator of mTORC1 signaling in the liver, and the plasma Fischer's ratio is partially reflected by mTORC1 signaling in the liver and muscle.

Interestingly, the expression of c-myc was correlated significantly with BCAT1 (Figure 1C) as reported previously.¹⁵ Several studies observed up-regulated c-myc expression in advanced stages of CH-C¹⁹ but, on the other hand, c-myc recently was shown to be a target of

mTORC1 in hepatic cells.¹⁷ The existence of a feedback mechanism between c-myc and mTORC1 signaling to maintain liver homeostasis (Figure 1E) is plausible, although the precise mechanisms need to be confirmed.

Impaired mTORC1 signaling is suggested to affect the IFN- α -induced signaling pathway. To address this, the relationship between mTORC1 and IFN signaling was assessed using a cell culture system. In low-amino-acid medium ($\times 1/5$, $\times 1/30$, and $\times 1/100$ DMEM), expression of pSTAT1 was decreased substantially, correlating with the impaired mTORC1 signaling represented by decreased p-mTOR and pS6K expression in Huh-7 cells (Figure 2A).

The relationship between mTORC1 and IFN signaling was confirmed further by the knock-down experiment of Raptor, a specific subunit of mTORC1 (Figure 2B), although a more precise analysis should be performed to confirm this relationship. Importantly, when Huh-7 cells were stimulated by IFN- α , pSTAT1 induction was repressed significantly in low-amino-acid medium ($\times 1/5$ DMEM) or in Raptor knocked-down conditions (Figure 2C). It therefore could be speculated that IFN treat-




Figure 6. Expression of S6K, STAT1, Foxo3a, Socs3, and HCV core in H77S.3/GLuc2A-transfected Huh-7.5 cells or continuously JFH-1-infecting Huh-7 cells supplemented with BCAA.

ment of patients with liver malnutrition and impaired mTORC1 signaling would lead to reduced induction of ISGs. Importantly, BCAA was able to restore impaired IFN signaling through increased binding of ISGF3 γ to its targets (Figure 2D–F).

Besides cross-talk of mTORC1 and IFN signaling, we revealed that Foxo3a also is involved in the IFN inhibitory pathway. In low-amino-acid medium, expression of pFoxo3a (ser253) was decreased substantially whereas that of Socs3 was increased. A decreased pFoxo3a/Foxo3a ratio indicates nuclear accumulation of Foxo3a before activation of its target genes, and this was confirmed by immunofluorescent staining (Figure 3C). The expression of Foxo3a was significantly positively correlated with that of Socs3 in CH-C liver (Figure 3F). These findings prompted us to identify a putative FBE in the Socs3 promoter region (Figure 4A). In fact, Socs3 promoter reporter activity was activated by overexpression of Foxo3a, and mutation of FBE impaired Foxo3a-dependent Socs3 promoter activation. Conversely, induction of Socs3 was not observed when expression of Foxo3a was knocked down by siRNA in low-amino-acid medium. Socs3 induction in low-amino-acid medium was owing to increased binding of Foxo3a to the FBE, which was confirmed by ChIP (Figure 4D). Therefore, in addition to impaired mTORC1 signaling, the Foxo3a-mediated Socs3 IFN inhibitory pathway might be involved in impaired IFN signaling in patients with liver malnutrition (Figure 4E).

Finally, we examined whether BCAA could restore impaired IFN signaling and inhibit HCV replication in cells

under conditions of malnutrition. Importantly, BCAA could repress replication of the recombinant genotype 1a-derived HCV, H77S.3/GLuc2A, in a dose-dependent manner (Figure 5A). H77S.3/GLuc2A RNA produces infectious virus¹⁴ and, therefore, the results indicate that BCAA might act on a naive HCV infection. Moreover, BCAA inhibited JFH-1-infected Huh-7 cells in which JFH-1 continuously was infecting in a dose-dependent manner. These results indicate that BCAA had an inhibitory effect on either naive or persistent HCV infection irrespective of genotypes (1a and 2a). Consistent with these results, BCAA induced the expression of pSTAT1 and Mx protein in a dose-dependent manner, and repressed Socs3 expression through increasing the ratio of pFoxo3a (ser243) to Foxo3a in a dose-dependent manner (Figures 5 and 6). Therefore, BCAA potentially could restore impaired IFN signaling and inhibit HCV replication in a CH-C state of malnutrition.

In conclusion, we addressed the clinical significance of the nutritional state of the liver on the treatment response of Peg-IFN and RBV combination therapy for CH-C. Although further studies are required to fully define the precise mechanisms underlying mTOR and IFN signaling, we showed that plasma values of Fischer's ratio are a useful nutritional parameter associated with treatment response. Fischer's ratio reflects mTORC1 signaling in the liver, which is correlated with IFN signaling and related to Socs3 IFN inhibitory signaling through Foxo3a. The potential usefulness of BCAA for the augmentation of IFN signaling could suggest a new therapeutic application for advanced-stage CH-C.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at doi: 10.1053/j.gastro.2011.03.051.

Appendix A

The Hokuriku Liver Study Group is composed of the following members: Drs Takashi Kagaya, Kuniaki Arai, Kaheita Kakinoki, Kazunori Kawaguchi, Hajime Takatori, and Hajime Sunakosaka (Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan); Drs Touru Nakahama and Shinji Kamiyamamoto (Kurobe City Hospital, Kurobe, Toyama, Japan); Dr Yasuhiro Takemori (Toyama Rosai Hospital, Uozu, Toyama, Japan); Dr Hikaru Oguri (Koseiren Namerikawa Hospital, Namerikawa, Toyama, Japan); Drs Yatsugi Noda and Hidero Ogino (Toyama Prefectural Central Hospital, Toyama, Japan); Drs Yoshinobu Hinoue and Keiji Minouchi (Toyama City Hospital, Toyama, Japan); Dr Nobuyuki Hirai (Koseiren Takaoka Hospital, Takaoka, Toyama, Japan); Drs Tatsuho Sugimoto and Koji Adachi (Tonami General Hospital, Tonami, Toyama, Japan); Dr Yuichi Nakamura (Noto General Hospital, Nanao, Ishikawa, Japan); Drs Masashi Unoura and Ryuhei Nishino (Public Hakui Hospital, Hakui, Ishikawa, Japan); Drs Hideo Morimoto and Hajime Ohta (National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan); Dr Hirokazu Tsuji (Kanazawa Municipal Hospital, Kanazawa, Ishikawa, Japan); Drs Akira Iwata and Shuichi Terasaki (Kanazawa Red Cross Hospital, Kanazawa, Ishikawa, Japan); Drs Tokio Wakabayashi and Yukihiko Shirota (Saiseikai Kanazawa Hospital, Kanazawa, Ishikawa, Japan); Drs Takeshi Urabe and Hiroshi Kawai (Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan); Dr Yasutsugu Mizuno (Nomi Municipal Hospital, Nomi, Ishikawa, Japan); Dr Shoni Kameda (Komatsu Municipal Hospital, Komatsu, Ishikawa, Japan); Drs Hirotohi Miyamori and Uichiro Fuchizaki (Keiju Medical Center, Nanao, Ishikawa, Japan); Dr Haruhiko Shyugo (Kanazawa Arimatsu Hospital, Kanazawa, Ishikawa, Japan); Dr Hideki Osaka (Yawata Medical Center, Komatsu, Ishikawa, Japan); Dr Eiki Matsushita (Kahoku Central Hospital, Tsubata, Ishikawa, Japan); Dr Yasuhiro Katou (Katou Hospital, Komatsu, Ishikawa, Japan); Drs Nobuyoshi Tanaka and Kazuo Notsumata (Fukuiken Saiseikai Hospital, Fukui, Japan); Dr Mikio Kumagai (Kumagai Clinic, Tsuruga, Fukui, Japan); and Dr Manabu Yoneshima (Municipal Tsuruga Hospital, Tsuruga, Fukui, Japan).

References

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–982.

2. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105–1109.
3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399–401.
4. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. *Gastroenterology* 2010;139:499–509.
5. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. *Gastroenterology* 2010;139:120–129 e18.
6. Nishitani S, Ijichi C, Takehana K, et al. Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. *Biochem Biophys Res Commun* 2004;313:387–389.
7. Matsumura T, Morinaga Y, Fujitani S, et al. Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver. *Hepatology* 2005;33:27–32.
8. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 2002;110:163–175.
9. Colina R, Costa-Mattioli M, Dowling RJ, et al. Translational control of the innate immune response through IRF-7. *Nature* 2008;452:323–328.
10. Kaur S, Lal L, Sassano A, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. *J Biol Chem* 2007;282:1757–1768.
11. Shimbo K, Kubo S, Harada Y, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. *Biomed Chromatogr* 2009;24:683–691.
12. Shirasaki T, Honda M, Mizuno H, et al. La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication. *J Infect Dis* 2010;202:75–85.
13. Yi M, Villanueva RA, Thomas DL, et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc Natl Acad Sci U S A* 2006;103:2310–2315.
14. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. *Gastroenterology* 2011;140:667–675.
15. Eden A, Simchen G, Benvenisty N. Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. *J Biol Chem* 1996;271:20242–2045.
16. Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. *Science* 2010;328:1172–1176.
17. Telean AA, Hietakangas V, Sayadian AC, et al. Nutritional control of protein biosynthetic capacity by insulin via Myc in *Drosophila*. *Cell Metab* 2008;7:21–32.
18. Zhang X, Gan L, Pan H, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. *J Biol Chem* 2002;277:45276–45284.
19. Farinati F, Cardin R, Bortolami M, et al. Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. *World J Gastroenterol* 2006;12:2065–2069.

Received October 19, 2010. Accepted March 18, 2011.

Reprint requests

Address requests for reprints to: Shuchi Kaneko, MD, PhD,
Department of Gastroenterology, Graduate School of Medicine,
Kanazawa University, Takara-Machi 13-1, Kanazawa 920-8641,
Japan. e-mail: skaneko@m-kanazawa.jp; e-mail: fax: (81) 76-234-
4250.

Acknowledgments

Participating investigators from the Hokuriku Liver Study Group are listed in Appendix A.

The authors thank Mina Nishiyama and Yuki Hatayama for excellent technical assistance.

Conflicts of interest

The authors disclose no conflicts.

Supplementary Materials and Methods

Plasma Amino Acid Analysis

Plasma sample amino acid concentrations were measured by high-performance liquid chromatography-electrospray ionization-mass spectrometry followed by derivatization.¹ An MSQ Plus LC/MS system (Thermo Fischer Scientific, Waltham, MA) equipped with an electrospray ionization source was used in positive ionization mode for selected ion monitoring. Xcalibur version 1.4 SR1 software (Thermo Fischer Scientific, Yokohama, Japan) was used for data collection and processing. The high-performance liquid chromatography separation system consisted of an L-2100 pump, L-2200 autosampler, and L-2300 column oven (Hitachi High-Technologies Corporation, Tokyo, Japan). A Wakosil-II 3C8-100HG column (100, 2.1, 3 mm; Wako Pure Chemical Industries, Osaka, Japan) was used for the separation, and the mobile phase consisted of eluent A (25-mmol/L ammonium formate in water, pH 6.0) and eluent B (water:acetonitrile = 40:60).

Western Blotting

The expression of HCV core protein, Socs3, Foxo3a, phospho-Foxo3a (Ser253) (pFoxo3a), STAT1, pSTAT1 (Tyr701), S6K, pS6K, p-mTOR (Ser2448), Raptor, and β -actin were evaluated with mouse anti-core (Affinity BioReagents, Golden, CO), mouse anti-Socs3 (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-Foxo3a, rabbit anti- β -actin (Sigma-Aldrich, St Louis, MO), rabbit anti-phospho-Foxo3a (Ser253), rabbit anti-STAT1, rabbit anti-p-STAT1 (Tyr701), rabbit anti-p70 S6K, rabbit anti-pS6K, rabbit anti-p-mTOR (Ser2448), and rabbit anti-Raptor (Cell Signaling Technology, Beverly, MA), respectively. Densitometric analysis was conducted directly on the blotted membrane using a charge coupled device camera system (LAS-3000 Mini; Fujifilm, Tokyo, Japan) and Scion Image software (Frederick, MD).

Primer Sequences for PCR and siRNA

Primer sequences for PCR and siRNA were as follows: 2'5'OAS: forward 5'- CTC AGA AAT ACC CCA GCC AAA TC-3', reverse 5'-GTG GTG AGA GGA CTG AGG AA-3'; Socs3: forward 5'-TAC CAC CTG AGT CTC CAG CTT CTC-3', reverse 5'-CCT GGC AGT TCT CAT TAG TTC AGC ATT C-3'; Foxo3a: forward 5'-TGC TGT ATG CAA GAA CTT TCC AGT AGC AG-3', reverse 5'-ACT CTA GCC CCC ATG CTA CTA GTG-3'; glyceraldehyde-3-phosphate dehydrogenase: forward 5'-GAA GGT GAA GGT CGG AGT-3', reverse 5'-GAA GAT GGT GAT GGG ATT TC-3', siFoxo3a (SASI_Hs01_00119127; Sigma) sense: 5'-GAA UGA UGG GCU GAC UGA AdTdT-3', antisense: 5'-UUC AGU CAG CCC AUC AUU CdTdT-3'. Small interfering Raptor was purchased as

part of KIAA1303 siGENOME SMART pool siRNA reagents from Dharmacon, Inc (Lafayette, CO).

Construction of ISRE-Luc Reporter and FBEmut-luc Reporter Plasmids

Oligonucleotides containing the ISRE tandem repeat sequence (sense 5'-TCG AGA ACT GAA ACT GAA ACT GAA ACT GAA ACT GAA ACT GAA ACT GAA ACT GAA ACT A-3', antisense 5'-AGC TTT TCA GTT TCA GTT TCA GTT TCA GTT TCA GTT TCA GTT TCA GTT TCA GTT C-3', consensus 5'-GAA Ann GAA ACT-3') were annealed, and integrated into Xho I and Hind III sites of the pGL4.23 luciferase vector (Promega). The human Socs3 promoter region (-109/+217) was amplified by genomic PCR using specific primers (forward, 5'-TGC TGC GAG TAG TGA CTA AAC ATT ACA AG-3' and reverse, 5'-CCG TGA AGT CCA CAA AGG AGC CTT C-3') and cloned into the EcoR V site of the pGL4.10-luc2 reporter vector (Promega). The Socs3 FBE mutant reporter vector was created by substituting 2 adenines in the putative FBE with guanines (wild-type sequence 5'-CTAAACA-3', mutated sequence 5'-CTGAGCA-3').

ChIP Assay

For the ChIP assay using the anti-ISGF3 γ antibody, 1×10^6 Huh-7 cells were treated with IFN- α (0 or 100 U/mL) and BCAA (2 mmol/L) in low-amino-acid medium for 6 hours. For ChIP using the anti-Foxo3a antibody, 1×10^6 Huh-7 cells were cultured in low-amino-acid medium for 24 hours.

Cells were cross-linked with 1% formaldehyde in PBS for 10 minutes at 37°C, and the reaction was stopped with 250 mmol/L glycine for 10 minutes. Cells were suspended in sodium dodecyl sulfate-lysis buffer (1% sodium dodecyl sulfate, 10 mmol/L ethylenediaminetetraacetic acid [EDTA], 50 mmol/L Tris-HCl [pH 8.1]), complete protease inhibitor cocktail (Roche Applied Science), and incubated for 30 minutes at 10°C. Cell lysate was sonicated with Bioruptor (Cosmo Bio, Tokyo, Japan) to obtain chromatin fragments and diluted 10-fold in ChIP dilution buffer (0.01% sodium dodecyl sulfate, 1.1% Triton-X 100, 1.2 mmol/L EDTA, 16.7 mmol/L Tris-HCl [pH 8.1], 150 mmol/L NaCl, complete protease inhibitor cocktail). Chromatin fragments were incubated with 2 μ g ISGF3 γ antibody (Santa Cruz Biotechnology), 2 μ g Foxo3a antibody (H-144; Santa Cruz Biotechnology), or normal rabbit immunoglobulin G for 18 hours at 4°C. Dynabeads (30 μ L) protein G (Invitrogen) was added and incubated for 1 hour at 4°C. The beads were washed with low-salt-wash buffer (0.1% sodium dodecyl sulfate, 1% Triton-X 100, 2.0 mmol/L EDTA, 20 mmol/L Tris-HCl [pH 8.1], 150 mmol/L NaCl), high-salt-wash buffer (0.1% sodium dodecyl sulfate, 1% Triton-X 100, 2.0 mmol/L EDTA, 20 mmol/L Tris-HCl [pH 8.1], 500 mmol/L NaCl), LiCl wash buffer (250 mmol/L LiCl, 1% NP-40, 1% de-

oxycholate, 1.0 mmol/L EDTA, 1.0 mmol/L Tris-HCl [pH 8.1]) and Tris-EDTA buffer. Immunoprecipitated chromatin fragments were eluted with elution buffer (1% sodium dodecyl sulfate, 100 mmol/L NaHCO₃, 10 mmol/L dithiothreitol), and reverse cross-linked by incubating for 6 hours at 65°C in elution buffer containing 200 mmol/L NaCl. DNA fragments were purified and quantified by real-time detection PCR with primers for putative ISRE in the 2'5'OAS promoter region (forward, 5'-AAA TGC ATT TCC AGA GCA GAG TTC AGA G-3', reverse, 5'-GGG TAT TTC TGA GAT CCA TCA TTG ACA GG-3') or putative FBE in the Socs3 promoter region (forward, 5'-TGC TGC GAG TAG TGA CTA AAC ATT ACA AG -3', reverse, 5'-AGC GGA GCA GGG AGT CCA AGT C -3'). Values were normalized by the measurement of input DNA.

pH77S.3/GLuc2A

pH77S.2 is a modification of pH77S² containing an additional mutation within the E2 protein (N476D in the polyprotein) that promotes infectious virus yields from RNA-transfected cells (Yi et al, unpublished data). To monitor replication, the GLuc sequence, fused at its C terminus to the foot-and-mouth disease virus 2A auto-protease, was inserted between p7 and NS2 of pH77S.2 (Supplementary Figure 4). To insert the GLuc-coding sequence between p7 and NS2 in pH77S.2, followed by the foot-and-mouth disease virus 2A protein-coding sequence, Mlu I, EcoR V, and Spe I restriction sites were created between the p7 and NS2 coding sequences by site-directed mutagenesis. DNA coding for GLuc was subcloned into the Mlu I and EcoR V sites of the modified plasmid after PCR amplification using the primers: 5'-ATA ATA TTA CGC GTA TGG GAG TCA AAG TTC TGT TTG CC-3' (sequence corresponding to the N-terminal GLuc is italicized and that corresponding to Mlu I is underlined) and 5'-ATA AAT AGAT ATC GTC ACC ACC GGC CCC CTT GAT CTT-3' (C terminal GLuc is italicized and EcoR V is underlined). A DNA fragment encoding the 17 amino acids of the foot-and-mouth disease virus 2A protein was generated by annealing the following complementary oligonucleotides: 5'-ATA TGA TAT CAA CTT TGA CCT TCT CAA GTT GGC CGG CGA CGT

CGA GTC CAA CCC AGG GCC CAC TAG CAT AT-3' and 5'-ATA TGC TAG TGG GCC CTG GGT TGG ACT CGA CGT CGC CGG CCA ACT TGA GAA GGT CAA AGT TGA TAT CAT AT-3' (underlined sequences indicate EcoR V and Spe I sites). The annealed oligonucleotides were digested by both restriction enzymes and the product inserted into the corresponding sites of pH77S.2 containing GLuc to generate pH77S.2/GLuc2A. Q41R is a cell-culture adaptive mutation within the NS3 protease domain of pH77S. Because it is not essential for production of infectious virus (Yi et al, unpublished data), pH77S.2 and pH77S.2/GLuc2A constructs underwent this mutation by site-directed mutagenesis of a PCR fragment spanning the Afe I and BsrG I sites to replace Gln₄₁ with wild-type Arg. The resulting plasmids (pH77S.2/R41Q and pH77S.2/GLuc2A/R41Q) were redesignated pH77S.3 and pH77S.3/GLuc2A, respectively.^{3,4} GLuc has several advantages over other luciferase reporter enzymes in that it is smaller and allows more sensitive detection than either firefly or Renilla luciferase.^{3,4} In addition, a signal sequence directs its secretion into cell-culture media, allowing real-time dynamic measurements of GLuc expression without the need for cell lysis. H77S.3/GLuc2A RNA produces infectious virus, although with lower efficiency than H77S.3 RNA (10-fold less).

References

1. Shimbo K, Kubo S, Harada Y, et al. Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. *Biomed Chromatogr* 2009; 24:683–691.
2. Yi M, Villanueva RA, Thomas DL, et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc Natl Acad Sci U S A* 2006;103:2310–2315.
3. Shetty S, Kim S, Shimakami T, et al. Hepatitis C virus genomic RNA dimerization is mediated via a kissing complex intermediate. *RNA* 2010;16:913–925.
4. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. *Gastroenterology* 2011; 140:667–675.

Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after LDLT

Akihisa Nagatsu, Masahiko Taniguchi, Tsuyoshi Shimamura, Tomomi Suzuki, Kenichiro Yamashita, Hiroshi Kawakami, Daisuke Abo, Toshiya Kamiyama, Hiroyuki Furukawa, Satoru Todo

Akihisa Nagatsu, Toshiya Kamiyama, Satoru Todo, Department of General Surgery, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan
Masahiko Taniguchi, Tomomi Suzuki, Hiroyuki Furukawa, Department of Organ Transplantation and Regeneration, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan

Tsuyoshi Shimamura, Division of Organ Transplantation, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan

Kenichiro Yamashita, Department of Molecular Surgery, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan

Hiroshi Kawakami, Department of Gastroenterology, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan

Daisuke Abo, Department of Radiology, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan

Author contributions: Nagatsu A contributed to this work mainly; Nagatsu A, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Kamiyama T, Furukawa H, Todo S, Kawakami H and Abo D provided medical care; Nagatsu A and Taniguchi M wrote the paper.

Correspondence to: Masahiko Taniguchi, MD, Department of Organ Transplantation and Regeneration, Graduate School of Medicine, Hokkaido University, N-15 W-7, Kita-ku, 060-8638 Sapporo, Japan. tonny@isis.ocn.ne.jp

Telephone: +81-11-7065927 Fax: +81-11-7177515

Received: October 27, 2010 Revised: January 4, 2011

Accepted: January 11, 2011

Published online: August 14, 2011

endoscopic treatment was effective against pancreatic fistulas that developed after LDLT. In case 1, a 61-year-old woman underwent LDLT for primary biliary cirrhosis. Because of a portal venous thrombus caused by a splenorenal shunt, the patient underwent portal vein reconstruction, and a splenorenal shunt was ligated on post-operative day (POD) 7. The main pancreatic duct was injured during the manipulation to achieve hemostasis, thereby necessitating open drainage. However, discharge of pancreatic fluid continued even after POD 300. Endoscopic naso-pancreatic drainage (ENPD) was performed, and this procedure resulted in a remarkable decrease in drain output. The refractory pancreatic fistula healed on day 40 after ENPD. In case 2, a 58-year-old man underwent LDLT for cirrhosis caused by the hepatitis C virus. When the portal vein was exposed during thrombectomy, the pancreatic head was injured, which led to the formation of a pancreatic fistula. Conservative therapy was ineffective; therefore, ENPD was performed. The pancreatic fistula healed on day 38 after ENPD. The findings in these 2 cases show that endoscopic drainage of the main pancreatic duct is a less invasive and effective treatment for pancreatic fistulas that develop after LDLT.

© 2011 Baishideng. All rights reserved.

Key words: Pancreatic fistula; Endoscopic treatment; Living donor liver transplantation; Complications

Peer reviewer: Marco Vivarelli, MD, Assistant Professor, Department of Surgery and Transplantation, University of Bologna, S. Orsola Hospital, 40123 Bologna, Italy

Abstract

Pancreatic fistula is a quite rare complication in patients who undergo living donor liver transplantation (LDLT). However, in the cases that show pancreatic fistula, the limited volume of the graft and the resultant inadequate liver function may complicate the management of the fistula. As a result, the pancreatic fistula may result in the death of the patient. We present 2 cases in which

Nagatsu A, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Kawakami H, Abo D, Kamiyama T, Furukawa H, Todo S. Endoscopic naso-pancreatic drainage for the treatment of pancreatic fistula occurring after LDLT. *World J Gastroenterol* 2011; 17(30): 3560-3564 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v17/i30/3560.htm> DOI: <http://dx.doi.org/10.3748/wjg.v17.i30.3560>